Review of Gastrointestinal Carcinoid Tumors: Latest Therapies
|
|
- Christopher Craig
- 5 years ago
- Views:
Transcription
1 Review of Gastrointestinal Carcinoid Tumors: Latest Therapies Arvind Dasari, MD, MS Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston, TX, USA
2 Neuroendocrine Tumors (NET) Incidence Incidence Trends Incidence Trends of NETs and all malignant neoplasms from (age adjusted to 2000 US Standard Population) Incidence Trends of NETs and all malignant neoplasms from (age adjusted to 2000 US Standard Population) Surveillance Research Program, National Cancer Institute SEER*Stat software (seer.cancer.gov/seerstat) ver November 2014 Dasari et al. JAMA Oncol Oct 1;3(10):
3 NETs : Prevalence Incidence Trends of NETs and all malignant neoplasms from (age adjusted to 2000 US Standard Population) 20-year Limited Duration Prevalence projected into US Population on 1/1/2014 : 171,321 Surveillance Research Program, National Cancer Institute SEER*Stat software (seer.cancer.gov/seerstat) ver November 2014 Dasari et al. JAMA Oncol Oct 1;3(10):
4 NETs : Evolving Classification 2010 Grade 1 Grade 2 Grade 3 Ki-67 <3% 3-20% >20% Mitotic Index (10HPF) < >20 Differentiation Well Poor 2017 Ki-67 Grade 1 Grade 2 Grade 3 <3% 3-20% >20% >20% Mitotic Index (/10 HPF) <2/ >20 >20 Differentiation Well Well Well Poor Small Cell Large Cell Sorbye et al, Cancer 2014 Sept 15; 120(18): Kim et al, Ann Diagn Path 2017 Aug;29:11-16
5 Somatostatin Physiology Found in CNS and peripheral tissues Binds to five somatostatin receptors: sst1-5 Inhibitory effects on secretion & growth Aliment Pharmacol Ther Jan 15;31(2):169-88
6 Hormone Control Somatostatin Analogues Compound Peptide size (#Amino Acids) t 1/2, Delivery Long Acting Formula, Delivery Binding Affinity Somatostatin 14 / min, iv All receptors FDA Approved Indications Octreotide 8 2 hrs, sc Octreotide LAR, IM q 4 wks Lanreotide 8 2 hrs, sc Lanreotide PR: IM q 2 wks Lanreotide AG: SC q4 wks Pasireotide 6 12 hrs, sc Pasireotide LAR: IM sst2 >> sst5 sst2 >> sst5 sst 1,2,3,5 Acromegaly Carcinoid syndrome VIPomas Acromegaly Gastroenter opancreatic NETs Carcinoid Syndrome Acromegaly Enzler et al, Semin Oncol, 2017 April;44(2): Octreotide, Lanreotide & Pasireotide Package Inserts.
7 Lanreotide ELECT Trial Advanced NETs with carcinoid syndrome, n = 115 R Lanreotide 120 mg sc q28 d + sc octreotide Placebo + sc octreotide Primary Endpoint: Adjusted mean percent of days sc octreotide used over 16-weeks Percent of days of sc octreotide Number of days of sc octreotide use Complete Success: No use Partial success : 1-3 days Treatment Failure: > 3 days Odds of full / partial success: 2.4; p = Vinik et al Endocr Pract. 2016;22:
8 Diarrhea Control Telotristat 4 BM (Mean 5-6) Rescue sc octreotide and anti-diarrheals allowed Baseline Characteristics: Mean BM = 5-6 / day Flushing = 2-3 / day Urine 5-HIAA = (58% with elevation) Adapted from Dr. Kulke s presentation at 18 th ECCO-40 th ESMO European Cancer Congress, Sept 29, 2015
9 Diarrhea Control Telotristat Mean reduction in BM# Placebo Telotristat 250 tid Telotristat 500 tid Responders* Urine 5-HIAA #Hodges-Lehman estimator for reduction in BM: (250 mg) & (500 mg) *Defined as 30% reduction in BM for 50% days **Small number of patients with significant flushing and abdominal pain at baseline and no change during study period Adapted from Dr. Kulke s presentation at 18 th ECCO-40 th ESMO European Cancer Congress, Sept 29, 2015
10 Tumor Control Drug Approvals Approved agents for oncologic control before 2011 pnets: Streptozocin GI NETs: None Approved agents for oncologic control pnets: Everolimus, sunitinib, lanreotide GI NETs: Lanreotide, everolimus Lung Nets: Everolimus Other active agents pnets: Temozolomide GI NETs: Octreotide, (177)Lu-DOTATATE / / OCT SC CS 25,30 LAN symptom control 24 PROMID OCT LAR: Antitumor activity 9,31 CLARINET LAN GEP NET 16,17,29 RADIANT-4 EVE NF GI and lung NET 15,19 Treatments 1982 STZ pnet STZ combination: Survival benefit pnet 2 OCT LAR carcinoid tumors 23,26, /11 RADIANT-3 EVE in pnet 11,12,32,33 Sunitinib phase III pnet 13,31,34 ELECT LAN: Symptom control TELESTAR telotristat etiprate CS 20 NDA filed 3/30/16 US approval US/EU approval EU approval RADIANT-2 EVE + OCT, LAR in mnet w/cs 14 NETTER Lu-Dotatate midgut NET 18 AC, atypical carcinoid; AJCC; American Joint Committee on Cancer; CS, carcinoid syndrome; ENETS, European Neuroendocrine Tumor Society; ESMO; European Society for Medical Oncology; EVE, everolimus; GEP, gastroenteropancreatic; GI NETs, gastrointestinal neuroendocrine tumors; LAN, lanreotide; LAR, long-acting repeatable; m, metastatic; NANETS, North American Neuroendocrine Tumor Society; NEC, neuroendocrine carcinomas; NET, neuroendocrine tumors; NF, nonfunctional; OCT, octreotide; pnet, pancreatic NET; SC, subcutaneous; STZ, streptozocin; TC, typical carcinoid; UICC, Union for International Cancer Control; WHO, World Health Organization LAN symptom control
11 NETs : Pancreatic (pnet) vs Carcinoids Median overall survival (months) Lung Stomach Pancreas Small Intestine Cecum Colon Rectum Yao et al, 2008 J Clin Oncol 26(18):
12 pnet - Temozolomide Advanced pnet n = 143 Capecitabine 750 mg/m 2 BID Days 1-14 Temozolomide 200 mg/m 2 QD Days Median # of cycles = 9 Overall Survival 73.2 (95% CI ) months PFS 17 (95% CI 15 25) months Response Rate = 54% Cives et al. Endocr Relat Cancer 2016;23:
13 pnet - Temozolomide Advanced pnet n = 143 Capecitabine 750 mg/m 2 BID Days 1-14 Temozolomide 200 mg/m 2 QD Days Median # of cycles = 9 E2211: PI Pamela Kunz, MD Phase II Temozolomide + / - Capecitabine n = 138, Primary End Point: PFS Accrual Completed Overall Survival 73.2 (95% CI ) months PFS 17 (95% CI 15 25) months Response Rate = 54% Cives et al. Endocr Relat Cancer 2016;23:
14 pnet - Sunitinib Updated OS (2017) Sunitinib 38.6 mo Placebo 29.1 mo* HR 0.73, p = * 69% crossover Raymond et al. N Engl J Med 2011; Feb 10;364(6): Faivre et al. Ann Oncol 2017 Feb 1;28(2):
15 pnet Everolimus (RADIANT-3) *89% crossover Yao et al, 2011, N Engl J Med, Feb 10;364(6): Yao et al, 2016, J Clin Oncol Sep 12
16 Carcinoids Everolimus (RADIANT-4) Advanced, nonfunctioning, GI or Lung NETs N=302 R (2:1) Everolimus 10 mg QD Placebo Baseline Characteristics Variable Everolimus Placebo Male - n(%) 89 (43) 53 (55) Age - yr Time since diagnosis (median, mo) Prior SSA Therapy 109 (53%) 54 (56%) Origin n (%) Lung Midgut Hindgut Unknown/Other 63 (31) 72 (35) 34 (17) 36 (18) 27 (28) 32 (32) 19 (20) 19 (20) Yao et al. Lancet 2016 Mar 5;387(1022)
17 Carcinoids Everolimus (RADIANT-4) Yao et al. Lancet 2016 Mar 5;387(1022)
18 Everolimus Stomatitis (SWISH TRIAL) Rugo et al. J Clin Oncol.2016;34(suppl):Abstract 525
19 SSA for Tumor Control : PROMID Trial Advanced, mid-gut NETs N=85 R Octreotide 30 mg IM q28 d Placebo Overall Survival Time to Progression Rinke et al, Neuroendocrinology 2017;104(1):26-32 Rinke et al, J Clin Oncol 2009 Oct 1;27(28);
20 SSA for Tumor Control : CLARINET Trial Advanced, nonfunctioning Gastroenteropanc reatic NETs N=204 R Lanreotide 120 mg sc q28 d Placebo Baseline Characteristics Variable Lanreotide Placebo Male - n(%) 53 (52) 54 (52) Age - yr Time since diagnosis (median, mo) Origin n (%) Pancreas Midgut Hindgut Unknown/Other 42 (42) 33 (33) 11 (11) 15 (15) 49 (48) 40 (39) 3 (3) 11 (11) Tumor Progression: n (%) 4 (4) 5 (5) Caplin et al, N Engl J Med 2014;Jul 17;371(3)224-33
21 SSA for Tumor Control : CLARINET Trial Lanreotide Not reached Placebo 18.0 mo HR 0.47, p < Caplin et al, N Engl J Med 2014;Jul 17;371(3) Caplin et al. Endocr Relat Cancer 2016;23:
22 Peptide Receptor Radionuclide Therapy (PRRT) [ 111 In-DTPA 0 ]Octreotide [ 90 Y-DOTA 0,Tyr 3 ]Octreotide [ 177 Lu-DOTA0,Tyr 3 ]Octreotide [ 177 Lu-DOTA0,Tyr 3 ]Octreotate Bergsma et al, Best Practice & Research Clinical Gastroenterology 2012; 26:6,
23 PRRT Peptides and Radionuclides Affinity Profiles of Peptides, IC 50 (SEM) Profiles of Key Radionuclides Peptide sstr2 sstr5 Somatostatin 2.7 (0.3) 4 (0.30) Octreotide 2 (0.7) 22(6) Nuclide Indium t 1/2 days Emission Depth Electrons γ 10 μm 550 μm DOTA- [Tyr3]Octreotide DOTA- [Tyr3]Octreotate 14(2.6) 393(84) 1.5(0.4) 547(160) Yttrium β 12 mm Lutetium β, γ 3 mm Dash et al, 2015, Cancer Biotherapy and Radiopharmaceuticals, 2014, 30:47-70.
24 Kwekkeboom, JCO, 2008:2124 PRRT: Retrospective Data
25 NETTER-1 Study Design SSR +ve, progressive midgut carcinoids, n = Lu-DOTA- Octreotate x 4 cycles Octreotide LAR 60 mg IM every 4 weeks 177 Lu-DOTATE Therapy: Gbq (200mCi) iv over 30 min every 8 weeks - Amino Acid solution iv for 4 hours - Octreotide 30 mg LAR 24 hours after therapy, continued monthly Median Time Since Diagnosis (years) 177 Lu-Dotate (n = 116) Octreotide LAR 60 mg (n = 113) Ileum 86 (73%) 82 (73%) SRS, Krenning scale grade 2/3/4 (%) 9%/29%/61% 11%/30%/59% Grade 1 76 (66%) 81 (72%) Non-SSA Systemic Therapy 5-HIAA (mg/24 h), mean, SD* 41% 45% 100 (183) 77 (83) No. of PRRT of administrations = 4 78/102 (77%) Not applicable Strosberg et al, New Eng J Med Jan 12;376(2):
26 NETTER-1 Results: PFS Median PFS 8.4 m vs not reached (estimate 40 m); HR 0.21, p < Strosberg et al, New Eng J Med Jan 12;376(2):
27 NETTER-1 Results HR for death = 0.40; p = (O-Brien-Fleming threshold for significance = ) Strosberg et al, New Eng J Med Jan 12;376(2):
28 NETTER-1 Grade 3 / 4 Toxicities 177 Lu-Dotate* Control* p Value Nausea / Vomiting 12 (11) 3 < Lymphopenia 10 (9) 0 < Thrombocytopenia 2 (2) 1(1) <0.001 Leukopenia 1 (1) *n(%) Strosberg et al, New Eng J Med Jan 12;376(2):
29 NETTER-1 Grade 3 / 4 Toxicities 177 Lu-Dotate* Control* p Value Long term risk of MDS: ~ 2-3% AML: ~ 1% Nausea / Vomiting 12 (11) 3 < Lymphopenia 10 (9) 0 < Thrombocytopenia 2 (2) 1(1) <0.001 Leukopenia 1 (1) *n(%) Strosberg et al, New Eng J Med Jan 12;376(2):
30 NETTER-1 Grade 3 / 4 Toxicities Toxicity Traditional Therapy PRRT p Liver 23 (31%) 10(59%) <0.001 Bone Marrow 54 (71%) 12(71%) 0.97 Kidney 27(36%) 5(29%) 0.63 Riff et al. Clin Nucl Med Nov;40(11):845-50
31 Treatment Landscape of Advanced NETs Site Octreotide Lanreotide 177 Lu- DOTATATE Streptozocin Sunitinib Everolimus Disease status Tx naïve Stable Progressive over 3 yrs Historical Progressive over 12 mo Progressive over 6 mo* Lung RADIANT4 Stomach CLARINET RADIANT4 Pancreas CLARINET Historical Phase III RADIANT3* Small bowel Appendix PROMID CLARINET NETTER-1 RADIANT4 Colon CLARINET RADIANT4 Rectum CLARINET RADIANT4 Unknown 1 RADIANT4 *RADIANT-3 requires documentation of progressive disease (PD) in the prior 12 months. RADIANT-4 requires documentation of PD during prior 6 months. Rinke A, et al. J Clin Oncol Caplin ME, et al. N Engl J Med Strosberg J, et al. N Engl J Med Raymond E, et al. N Engl J Med Yao JC, et al. J Clin Oncol Yao JC, et al. N Engl J Med Yao JC, et al. Lancet
32 Thank you for your attention!
Cutting Edge Treatment of Neuroendocrine Tumors
Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE
More informationCutting Edge Treatment of Neuroendocrine Tumors
Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE
More informationMEDICAL MANAGEMENT OF METASTATIC GEP-NET
MEDICAL MANAGEMENT OF METASTATIC GEP-NET Jeremy Kortmansky, MD Associate Professor of Clinical Medicine Yale Cancer Center DISCLOSURES: NONE Introduction Gastrointestinal and pancreatic neuroendocrine
More informationNuevas alternativas en el manejo de TNE avanzados
Nuevas alternativas en el manejo de TNE avanzados Jaume Capdevila Hospital Universitari Vall d Hebron Barcelona Coordinación científica: Dr. Fernando Rivera Hospital Universitario Marqués de Valdecilla,
More information2015: Year in Review Results of Recent Trials
2015: Year in Review Results of Recent Trials Pamela L. Kunz, MD Assistant Professor of Medicine / GI Oncology Director, Stanford NET Program Stanford University School of Medicine Disclosures Research
More informationTRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS
TRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS Jaume Capdevila Unitat de Tumors GI i Endocrins Hospital Universitari Vall d Hebron Barcelona Experts, acollidors i solidaris OUTLINE BACKGROUND
More informationEvaluation and Management of Neuroendocrine Tumors
Evaluation and Management of Neuroendocrine Tumors Jennifer Chan, MD, MPH Clinical Director, Program in Neuroendocrine and Carcinoid Tumors Dana-Farber/Brigham and Women's Cancer Center October 14, 2017
More informationSelection of Appropriate Treatment
Expert Review in Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Selection of Appropriate Treatment Reference Slide Deck Neuroendocrine Tumors (NETs): A Diverse Group of Malignancies
More informationTeresa Alonso Gordoa Servicio Oncología Médica Hospital Universitario Ramón y Cajal
Teresa Alonso Gordoa Servicio Oncología Médica Hospital Universitario Ramón y Cajal Incidence per 100,000 EPIDEMIOLOGY Incidence rates of neuroendocrine tumors by primary tumor site 1.4 1.2 1.0 0.8 0.6
More informationNET εντέρου Τι νεότερο/ Νέες μελέτες. Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ
NET εντέρου Τι νεότερο/ Νέες μελέτες Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ NET: A Diverse Group of Malignancies 1-3 Wide spectrum of malignancies arising in neuroendocrine cells throughout the body
More informationOPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS
OPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS Dr Mairéad McNamara Senior lecturer, University of Manchester & Honorary Consultant in Medical Oncology, The Christie NHS Foundation Trust
More informationJaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology
Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology OUTLINE Molecular Rationale for the use of SSAs in
More informationGI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust
GI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust Introduction Carcinoid was old term, introduced in 1906 by German pathologist Cancinoma like More recent
More informationWHAT TO EXPECT IN 2015? - Renuka Iyer, MD Associate Professor of Medicine, University at Buffalo Associate Professor of Oncology, Roswell Park Cancer
WHAT TO EXPECT IN 2015? - Renuka Iyer, MD Associate Professor of Medicine, University at Buffalo Associate Professor of Oncology, Roswell Park Cancer Institute Overview Diagnosis: Gallium scan Biomarkers
More informationRecent developments of oncology in neuroendocrine tumors (NETs)
Recent developments of oncology in neuroendocrine tumors (NETs) Marc Peeters MD, PhD Coordinator Multidisciplinary Oncological Center Antwerpen (MOCA) Head of the Oncology Department UZA, Professor in
More informationA New Proposal for Metabolic Classification of NENs Stefano Severi IRST Meldola Italy
RADIONUCLIDE THERAPY AND ALLIED SCIENCE President: Giovanni Paganelli Chairman: Maria Salvato Baltimore USA Domenico Barone Meldola Italy A New Proposal for Metabolic Classification of NENs Stefano Severi
More informationNew Developments in the Care and Management of Patients with Gastroenteropancreatic Neuroendocrine Tumors Dr. Tim Asmis The Ottawa Hospital Cancer
New Developments in the Care and Management of Patients with Gastroenteropancreatic Neuroendocrine Tumors Dr. Tim Asmis The Ottawa Hospital Cancer Centre MD, FRCPC CAGPO September 2018 Disclosures Consultant
More informationToward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives
Toward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives Moderator: Ashley Grossman, MD, FRCP Professor of Neuroendocrinology William Harvey Research Institute Barts
More informationGastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors
Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors Jaume Capdevila, MD, PhD Vall d'hebron University Hospital Vall d'hebron Institute of Oncology (VHIO)
More informationCollaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic Neuroendocrine Tumors
Collaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic Neuroendocrine Tumors Collaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic
More informationLu 177-Dotatate (Lutathera) Therapy Information
Lu 177-Dotatate (Lutathera) Therapy Information Information for Lu 177-dotatate therapy also known as Lutathera, for the treatment of metastatic midgut neuroendocrine tumor and other metastatic neuroendocrine
More informationHot of the press. Γρηγόριος Καλτσάς MD FRCP Καθηγητής Παθολογίας Ενδοκρινολογίας ΕΚΠΑ
Hot of the press Γρηγόριος Καλτσάς MD FRCP Καθηγητής Παθολογίας Ενδοκρινολογίας ΕΚΠΑ Outline Diagnostic developments Histopathology Molecular Therapeutic developments Results on PRRT Telotristat in carcinoid
More informationGEP NET: algoritmo terapeutico. Dottor Nicola Fazio
GEP NET: algoritmo terapeutico Dottor Nicola Fazio Basi per il trattamento Caratteristiche del paziente Caratteristiche del tumore P.S., sindrome, comorbidità Differenziazione, Ki-67 Imaging morfologico
More informationPrior Authorization Review Panel MCO Policy Submission
Prior Authorization Review Panel MCO Policy Submission A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.
More informationPANCREATIC NEUROENDOCRINE TUMORS DECEMBER 12, 2017 IF YOU EXPERIENCE TECHNICAL DIFFICULTY DURING THE PRESENTATION:
PANCREATIC NEUROENDOCRINE TUMORS DECEMBER 12, 2017 IF YOU EXPERIENCE TECHNICAL DIFFICULTY DURING THE PRESENTATION: CONTACT WEBEX TECHNICAL SUPPORT DIRECTLY AT: US TOLL FREE: 1-866-779-3239 TOLL ONLY: 1-408-435-7088
More informationTUMORES NEUROENDOCRINOS. Miguel Navarro. Salamanca
TUMORES NEUROENDOCRINOS Miguel Navarro. Salamanca Introduction to Neuroendocrine Tumours (NETs) NETs are relatively RARE At least 40 different entities are described arising in different organs. Different
More informationPancreatic Neuroendocrine Tumours
UCLH Cancer Collaborative Pancreas Update Meeting 12 th July 2017 Pancreatic Neuroendocrine Tumours Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior
More informationMEDICAL POLICY SUBJECT: PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT)
MEDICAL POLICY SUBJECT: PEPTIDE RECEPTOR PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including an Essential
More informationNET und NEC. Endoscopic and oncologic therapy
NET und NEC Endoscopic and oncologic therapy Classification well-differentiated NET - G1 and G2 - carcinoid poorly-differentiated NEC - G3 - like SCLC well differentiated NET G3 -> elevated proliferation
More informationEXOCRINE: 93% Acinar Cells Duct Cells. ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others
EXOCRINE: 93% Acinar Cells Duct Cells Digestive Enzymes Trypsin: Digests Proteins Lipases: Digests Fats Amylase: Digest Carbohydrates ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others Hormones Glucagon
More informationManagement of Neuroendocrine Tumors
Management of Neuroendocrine Tumors Professor Barbro Eriksson Department of Endocrine Oncology ENETS Centre of Excellence Uppsala University Hospital Diagnostic Challenges in NET Heterogeneous group of
More informationPeptide Receptor Radionuclide Therapy (PRRT) of NET
Peptide Receptor Radionuclide Therapy (PRRT) of NET Dr. Tuba Kendi Associate Prof of Radiology, Mayo Clinic, Rochester, MN 2014 MFMER slide-1 Relevant Financial Relationship(s) None Off Label Usage None
More informationThe PET-NET Study 2016 CNETS Grant Award
The PET-NET Study 2016 CNETS Grant Award CANM Meeting April 21, 2017 Hagen Kennecke, MD, MHA, FRCPC Medical Oncology, BC Cancer Agency Associate Professor, University of British Columbia Raja Ampat, Indonesia
More informationNET del pancreas ben differenziato: la terapia oncologica. Alfredo Berru: Università degli Studi di Brescia Azienda Ospedaliera Spedali Civili Brescia
NET del pancreas ben differenziato: la terapia oncologica Alfredo Berru: Università degli Studi di Brescia Azienda Ospedaliera Spedali Civili Brescia Systemic treatment op:ons Somatosta:n analogues Interpheron
More informationAn Immunotherapy Clinical Trial for NETs
An Immunotherapy Clinical Trial for NETs Pamela L. Kunz, MD Assistant Professor of Medicine / Oncology Stanford Cancer InsEtute March 1, 2015 Outline Clinical trial basics What have we learned from recent
More informationBackground. Capdevila J, et al. Ann Oncol. 2018;29(Suppl 8): Abstract 1307O. 1. Dasari A, et al. JAMA Oncol. 2017;3(10):
Efficacy of Lenvatinib in Patients With Advanced Pancreatic (pannets) and Gastrointestinal (ginets) WHO Grade 1/2 (G1/G2) Neuroendocrine Tumors: Results of the International Phase II TALENT Trial (GETNE
More informationNICaN Pancreatic Neuroendocrine Tumour SACT protocols. 1.0 Dr M Eatock Final version issued
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Pancreatic Neuro-endocrine Tumours Dr Martin Eatock, Consultant Medical Oncologist & on behalf of the GI Oncologists Group,
More informationTherapeutic Radiopharmaceuticals in Oncology
Therapeutic Radiopharmaceuticals in Oncology Policy Number: 6.01.60 Last Review: 9/2018 Origination: 9/2018 Next Review: 9/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationTreatment algorithm Neuroendocrine tumours. Gregory Kaltsas Endocrine Unit, Department of Pathophysiology, University of Athens, Greece
Treatment algorithm Neuroendocrine tumours Gregory Kaltsas Endocrine Unit, Department of Pathophysiology, University of Athens, Greece Outline Presenting a meaningful algorithm Means used to develop algorithm
More informationOctreotide LAR in neuroendocrine tumours a summary of the experience
Endocrinology in oncology Review article Octreotide LAR in neuroendocrine tumours a summary of the experience Agnieszka Kolasińska-Ćwikła, MD, PhD Department of Chemotherapy, Oncology Clinic, Maria Sklodowska-Curie
More informationQOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors
QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors Abstract C-33 Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday
More informationSystemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid
Systemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid The Medical Oncology Perspective Nevena Damjanov, MD Associate professor Abramson Cancer Center of the University
More informationSUPPLEMENTARY INFORMATION
Supplementary Table 1. Therapies for non-men1 pancreatic neuroendocrine tumours (NETs) (published after 2011) Somatostatin analogues Tumour type a Intervention Number of participants/information available
More informationNeuroendocrine Tumors: Just the Basics. George Fisher, MD PhD
Neuroendocrine Tumors: Just the Basics George Fisher, MD PhD Topics that we will not discuss Some types of lung cancer: Small cell neuroendocrine lung cancer Large cell neuroendocrine lung cancer Some
More informationNeuroendocrine Tumors Positron Emission Tomography (PET) Imaging and Peptide Receptor Radionuclide Therapy
Neuroendocrine Tumors Positron Emission Tomography (PET) Imaging and Peptide Receptor Radionuclide Therapy Lawrence Saperstein, M.D. Assistant Professor of Radiology and Biomedical Imaging Chief, Nuclear
More informationNEUROENDOCRINE TUMOURS Updated December 2015 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary)
NEUROENDOCRINE TUMOURS Updated December 2015 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Cynthia Card (Staff Medical Oncologist, University of Calgary)
More informationOVERVIEW OF THE DIAGNOSIS AND TREATMENT OF GI NETS
OVERVIEW OF THE DIAGNOSIS AND TREATMENT OF GI NETS Dr Christos G. Toumpanakis MD PhD FRCP FEBGH Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine
More informationAddison's disease Neuroendocrine tumors Paraneoplastic syndromes
Addison's disease Neuroendocrine tumors Paraneoplastic syndromes Miklós Tóth Professor of Medicine and Endocrinology 9 th April, 2018 Semmelweis University 2nd Department of Medicine Addison's disease
More informationPeptide Receptor Radionuclide Therapy using 177 Lu octreotate
Peptide Receptor Radionuclide Therapy using 177 Lu octreotate BLR Kam, Erasmus Medical Centre, Rotterdam DJ Kwekkeboom, Erasmus Medical Centre, Rotterdam Legal aspects As 177 Lu-[DOTA 0 -Tyr 3 ]octreotate
More informationTHERAPEUTIC RADIOPHARMACEUTICALS
UnitedHealthcare of California (HMO) UnitedHealthcare Benefits Plan of California (EPO/POS) UnitedHealthcare of Oklahoma, Inc. UnitedHealthcare of Oregon, Inc. UnitedHealthcare Benefits of Texas, Inc.
More informationThe Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review
Gastrointestinal Cancer The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review MICHAEL MICHAEL, a ROCIO GARCIA-CARBONERO, b MATTHIAS M. WEBER, c CATHERINE
More informationLe target therapy nei Tumori Neuroendocrini
Le target therapy nei Tumori Neuroendocrini Take home messages Franco Grimaldi SOC Endocrinologia e Malattie del Metabolismo Nutrizione Clinica Azienda Ospedaliero-Universitaria Santa Maria della Misericordia
More informationGuideline A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO)
A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Systemic Therapy of Incurable Gastroenteropancreatic Neuroendocrine Tumours S. Singh, D. Sivajohanathan, T.
More informationTheragnostics Neuroendocrine and Prostate Cancer
Theragnostics Neuroendocrine and Prostate Cancer Target Audience: Pharmacists ACPE#: 0202-0000-18-080-L01-P Activity Type: Knowledge-based Target Audience: ACPE#: Activity Type: Disclosures Financial:
More informationNET ΠΝΕΥΜΟΝΑ: τι νεότερο / νέες μελέτες
NETMASTERCLASS 2017: an interactive workshop NET ΠΝΕΥΜΟΝΑ: τι νεότερο / νέες μελέτες Νικόλαος Τσουκαλάς MD, MSc, PhD Ογκολόγος - Παθολόγος, MSc Βιοπληροφορική Επιμελητής Α, Ογκολογικό Τμήμα Νοσηλευτικό
More informationChair s presentation Lutetium (177lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Public slides Chair s presentation Lutetium (177lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease 2 nd Appraisal Committee meeting Committee
More informationMEDICAL POLICY EFFECTIVE DATE: 06/21/07 REVISED DATE: 05/14/08, 04/16/09, 03/18/10, 03/17/11, 03/15/12, 02/21/13, 02/20/14, 02/19/15
MEDICAL POLICY PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationMEDICAL POLICY SUBJECT: PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT)
MEDICAL POLICY SUBJECT: PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) POLICY NUMBER: 7.01.78 CATEGORY: Technology Assessment EFFECTIVE DATE: 06/21/07 REVISED DATE: 05/14/08, 04/16/09, 03/18/10, 03/17/11,
More informationAdvanced typical and atypical carcinoid tumours of the lung: management recommendations
REVIEW ARTICLE Advanced typical and atypical carcinoid tumours of the lung: management recommendations B. Melosky md* ABSTRACT Background Neuroendocrine tumours (nets) are classified by site of origin,
More informationPancreatic NeuroEndocrine Tumors. Prof Eric Van Cutsem, MD, PhD Gastroenterology/Digestive Oncology Leuven, Belgium
Pancreatic NeuroEndocrine Tumors Prof Eric Van Cutsem, MD, PhD Gastroenterology/Digestive Oncology Leuven, Belgium Epidemiology Overall incidence 1.8 to 2.6 SEER, Europe Peak in 5 th and 6 th decade Incidence
More informationGastroenteropancreatic Neuroendocrine Tumors
Gastroenteropancreatic Neuroendocrine Tumors Mauro Cives, MD 1 and Jonathan R. Strosberg, MD 2 1 Assistant Professor, University of Bari, Department of Biomedical Sciences and Human Oncology, Bari, Italy;
More informationSystematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors
At the Cutting Edge Received: February 29, 2016 Accepted: April 12, 2016 Published online: April 16, 2016 Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors Adrian Lee
More informationPRRT in Management of NETs. Ioannis Karfis, MD PhD Assistant Head of Clinic Nuclear Medicine Dept IJB, Brussels
PRRT in Management of NETs Ioannis Karfis, MD PhD Assistant Head of Clinic Nuclear Medicine Dept IJB, Brussels THERAPEUTIC TARGETS in NENs Pavel M: Neuroendocrinology 2013;97:99-112 THERAPEUTIC ARENA in
More informationlutetium ( 177 Lu) oxodotreotide 370MBq/mL solution for infusion (Lutathera ) SMC No 1337/18 Advanced Accelerator Applications
lutetium ( 177 Lu) oxodotreotide 370MBq/mL solution for infusion (Lutathera ) SMC No 1337/18 Advanced Accelerator Applications 8 June 2018 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationOngoing and future clinical investigation in GEP NENs
ESMO PRECEPTORSHIP PROGRAMME Multidisciplinary management, standards of care and future perspectives Lugano, Switzerland 13-14 April 2018 CHAIR: Nicola Fazio, Italy George Pentheroudakis, Greece Ongoing
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL NEUROENDOCRINE GASTRO-ENTERO-PANCREATIC TUMOURS GI Site Group Neuroendocrine gastro-entero-pancreatic tumours Authors: Dr.
More informationSession 6 NEW TECHNIQUES IN RADIATION TREATMENT. Chairman : Françoise MORNEX
Session 6 NEW TECHNIQUES IN RADIATION TREATMENT Chairman : Françoise MORNEX INTERNAL IRRADIATION FOR ENDOCRINE TUMORS Emmanuel DESHAYES INTERNAL IRRADIATION FOR ENDOCRINE TUMORS Dr Emmanuel DESHAYES Nuclear
More informationPANCREATIC NEUROENDOCRINE TUMOURS A
PANCREATIC NEUROENDOCRINE TUMOURS A RARE PANCREATIC TUMOUR David L Chan 1,2, Nick Pavlakis 1, Paul Roach 2, Dale Bailey 2, Jennifer Arena 3, Eva Segelov 4 1. Department of Medical Oncology, Royal North
More informationTheranostics in Nuclear Medicine
Theranostics in Nuclear Medicine Patrick FLAMEN, MD, PhD Head Nuclear Medicine Institut Jules Bordet Université Libre de Bruxelles (U.L.B.) n Theranostics in Nuclear Medicine n A form of (nuclear) diagnostic
More informationPNET 3/7/2015. GI and Pancreatic NETs. The Postgraduate Course in Breast and Endocrine Surgery. Decision Tree. GI and Pancreatic NETs.
GI and Pancreatic NETs The Postgraduate Course in Breast and Endocrine Surgery Disclosures Ipsen NET Advisory Board Marines Memorial Club and Hotel San Francisco, CA Eric K Nakakura San Francisco, CA March
More informationSIRT in the Management of Metastatic Neuroendocrine Tumors
SIRT in the Management of Metastatic Neuroendocrine Tumors Navesh K. Sharma, DO, PhD Assistant Professor, Departments of Radiation Oncology, Diagnostic Radiology and Nuclear Medicine Medical Director,
More informationAntiangiogenics are effective treatments in NETs
RENET: A randomized phase III trial comparing REgorafenib to placebo in patients with advanced, progressive, well-differentiated NEuroendocrine Tumors (NETs). Coordinators: Dr Julien Hadoux & Dr David
More informationTelotristat Ethyl (etiprate) : a new kid on the block Dr. Christos G. Toumpanakis MD PhD FRCP
Telotristat Ethyl (etiprate) : a new kid on the block Dr. Christos G. Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine
More informationNeuroendocrine Tumours If you don t suspect it you can t detect it! Dr JWS Devar HPB Surgeon University of Witwatersrand E-AHPBA CHBAH & WDGMC
Neuroendocrine Tumours If you don t suspect it you can t detect it! Dr JWS Devar HPB Surgeon University of Witwatersrand E-AHPBA CHBAH & WDGMC Case Study 43 yr old female with a history of a left mastectomy
More informationEXOCRINE: 93% Acinar Cells Duct Cells. ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others
EXOCRINE: 93% Acinar Cells Duct Cells Digestive Enzymes Trypsin: Digests Proteins Lipases: Digests Fats Amylase: Digest Carbohydrates ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others Hormones Glucagon
More informationImpact of Functioning Metastatic Neuroendocrine Tumors
Clinical Overview and Treatment Advances in Carcinoid Syndrome Sponsored by Lexicon Pharmaceuticals Impact of Functioning Metastatic Neuroendocrine Tumors Evaluation & Management 1 Presentation objectives
More informationNeuroEndocrine Tumors Diagnostic and therapeutic challenges: introduction
NeuroEndocrine Tumors Diagnostic and therapeutic challenges: introduction Prof Eric Van Cutsem, MD, PhD Gastroenterology/Digestive Oncology Leuven, Belgium Eric.VanCutsem@uzleuven.be Diagnostic & therapeutic
More informationDevelopment of New Treatment Modalities Oncolytic Viruses and Nanotechnique
Development of New Treatment Modalities Oncolytic Viruses and Nanotechnique By Professor Kjell Öberg, M.D., Ph.D. Dept. of Endocrine Oncology, University Hospital, Uppsala, Sweden Nashville Oct. 2011 Hallmarks
More informationCase Report. Ameya D. Puranik, MD, FEBNM; Harshad R. Kulkarni, MD; Aviral Singh, MD; Richard P. Baum, MD, PhD ABSTRACT
Case Report 8-YEAR SURVIVAL WITH A METASTATIC THYMIC NEUROENDOCRINE TUMOR: EMPHASIS ON REDEFINING TREATMENT OBJECTIVES USING PERSONALIZED PEPTIDE RECEPTOR RADIONUCLIDE THERAPY WITH 177 Lu- AND 90 Y-LABELED
More informationIART Cremona,
IART Cremona, 06-06-2018 Quale spazio per la terapia biologica? Nicola Fazio, M.D., Ph. D. Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumors European Institute of Oncology Milan, Italy
More informationLutetium-DOTA TATE Treatment of inoperable GEP NETs
Logo 177 Lutetium-DOTA TATE Treatment of inoperable GEP NETs Dr. Augusto Llamas-Olier. Nuclear medicine department. Dr. Maria Cristina Martínez*, Dr. Alfonso Lozano** and Dr. Augusto Llamas-Olier*. *Nuclear
More informationNEUROENDOCRINE TUMORS
NEUROENDOCRINE TUMORS A PRIMER FOR HEALTHCARE PROFESSIONALS Advocating the Right Team, the Right Treatment, at the Right Time for Neuroendocrine (NET) patients and physicians educating I funding I supporting
More informationTHERANOSTICS MOLEKULARE BILDGEBUNG MITTELS PET/CT
THERANOSTICS MOLEKULARE BILDGEBUNG MITTELS PET/CT UND RADIOREZEPTORTHERAPIE VON NET Richard P. Baum Klinik für Molekulare Radiotherapie / Zentrum für Molekulare Bildgebung (PET/CT) ENETS Center of Excellence,
More informationOberndofer 1907 Illeal Serotonin Secreting Tumor Carcinoid (Karzinoide)
GEP-NET Adel K. El-Naggar, M.D., Ph.D. The University of Texas MD Anderson Cancer Center, Houston, Texas Oberndofer 1907 Illeal Serotonin Secreting Tumor Carcinoid (Karzinoide) 1 Histogenesis 16 different
More informationFRANKLY SPEAKING ABOUT CANCER: NEUROENDOCRINE & CARCINOID TUMORS (NETS)
FRANKLY SPEAKING ABOUT CANCER: NEUROENDOCRINE & CARCINOID TUMORS (NETS) Gilda s Club Quad Cities November 5 th, 2018 Joseph Dillon, MD Neuroendocrine Tumor Clinic University of Iowa Hospitals & Clinics
More informationStrategies in the Management of Neuroendocrine Tumors. Dr. Jean Maroun Dr. Elena Tsvetkova
Strategies in the Management of Neuroendocrine Tumors Dr. Jean Maroun Dr. Elena Tsvetkova 1 A ZORSE 2 Neuroendocrine Tumour Classification Neuroendocrine Tumours Carcinoid Tumours Pancreatic Neuroendocrine
More informationRecent Advances in Gastrointestinal Cancers
Recent Advances in Gastrointestinal Cancers Ursina R. Teitelbaum, MD Section of Hematology/Oncology Abramson Cancer Center PENN 2016 Updates in Oncology June 23, 2016 none Disclosures ASCO 2016 Highlights:
More informationPrognostic factors and treatment of gastroenteropancreatic G3 neuroendocrine carcinomas.
Prognostic factors and treatment of gastroenteropancreatic G3 neuroendocrine carcinomas. Halfdan Sorbye Medical Oncologist Professor, MD Dept of Oncology Haukeland Univ Hospital Bergen, Norway Gastroenteropancreatic
More informationReview Article Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature
Hindawi International Journal of Surgical Oncology Volume 2017, Article ID 6424812, 14 pages https://doi.org/10.1155/2017/6424812 Review Article Management Options for Advanced Low or Intermediate Grade
More informationSystemic Therapy for Pheos/Paras: Somatostatin analogues, small molecules, immunotherapy and other novel approaches in the works.
Systemic Therapy for Pheos/Paras: Somatostatin analogues, small molecules, immunotherapy and other novel approaches in the works. Arturo Loaiza-Bonilla, MD, FACP Assistant Professor of Clinical Medicine
More informationSandostatin LAR. Sandostatin LAR (octreotide acetate) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.09 Subject: Sandostatin LAR Page: 1 of 5 Last Review Date: March 16, 2018 Sandostatin LAR Description
More informationClinical Roundtable Monograph
Clinical Roundtable Monograph Clinical Advances in Hematology & Oncology May 215 New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors Moderator Alexandria T. Phan, MD Director
More informationAn Overview of NETS. Richard R.P. Warner M.D
An Overview of NETS Richard R.P. Warner M.D Diagnosis and Treatment Approaches Carcinoid (and other NETs) not as benign as originally described 13-50% of all carcinoids have distant metastases when first
More informationNeuroendocrine Tumour Theranostics
Neuroendocrine Tumour Theranostics Lisa Bodei Director of Targeted Radionuclide Therapy Molecular Imaging and Therapy Service Memorial Sloan Kettering Cancer Center New York Friday, April 13, 2018 Disclosure
More informationPRESS RELEASE. Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
PRESS RELEASE Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA for Treatment of Gastroenteropancreatic Neuroendocrine Tumors First-in-class Therapy Demonstrated 79% Improvement
More informationUpdates in Pancreatic Neuroendocrine Carcinoma Highlights from the 2010 ASCO Annual Meeting. Chicago, IL, USA. June 4-8, 2010
HIGHLIGHT ARTICLE Updates in Pancreatic Neuroendocrine Carcinoma Highlights from the 2010 ASCO Annual Meeting. Chicago, IL, USA. June 4-8, 2010 Susan Alsamarai 1, Steven K Libutti 2, Muhammad Wasif Saif
More informationClinical Roundtable Monograph
Clinical Roundtable Monograph Clinical Advances in Hematology & Oncology April 2017 Recent Advances in the Management of Gastroenteropancreatic Neuroendocrine Tumors: Insights From the 2017 ASCO Gastrointestinal
More information*Bert Bakker was an employee of Novartis Pharmaceuticals Corporation until June 06, 2014.
Page 1 of 20 Accepted Preprint first posted on 15 September 2015 as Manuscript ERC-15-0314 1 2 Efficacy of Octreotide LAR in Neuroendocrine Tumors: RADIANT-2 Placebo Arm Post Hoc Analysis 3 4 Authors:
More informationSomatuline Depot. Somatuline Depot (lanreotide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.27 Subject: Somatuline Depot Page: 1 of 5 Last Review Date: December 8, 2017 Somatuline Depot Description
More informationEverolimus Plus Octreotide Long-Acting Repeatable in Patients With Advanced Lung Neuroendocrine Tumors
CHEST Original Research Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Advanced Lung Neuroendocrine Tumors Analysis of the Phase 3, Randomized, Placebo-Controlled RADIANT-2 Study LUNG
More information